All Articles
NTRK gene fusion adoption readiness in 3 European countries

NTRK gene fusion adoption readiness in 3 European countries

18 December, 2020

Neurotrophic receptor tyrosine kinase (NTRK) gene fusions are seen in a few rare cancer types and occur infrequently in some common cancers. Accurate identification of NTRK fusion-driven cancer has become clinically important due to recent FDA and EMA drug approvals that will render NTRK inhibitors available in the near future in the European markets.

Different methodologies (ie, NGS [next-generation sequencing], IHC [immunohistochemistry], PCR [polymerase chain reaction], FISH [fluorescence in situ hybridization]) can be used to detect NTRK gene fusions with different advantages and disadvantages in terms of resource efficiency, turnaround time, sensitivity, and specificity. To determine real-world laboratory readiness for NTRK adoption, we investigated current developments in methodologies for identifying NTRK fusions, used by 83 laboratories in EU3 (France, Spain, and Italy).

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

Public Relations & Investor Relations advisers

Alma PR
71-73 Carter Lane

Tel: +44 (0)20 3405 0205 or [email protected]

Caroline Forde
Robyn Fisher
Kieran Breheny